OBJECTIVES: Despite statins are accepted as standard for reducing CHD risk by ~30% via their influence on LDL-Cholesterol level, they do not prevent the majority  of clinical events  like MI, coronary death or stroke. In addition to other modifiable risk factors like hypertension or diabetes, persistent dyslipidemia, expressed as LDL-C above target and/or low HDL-Cholesterol (HDL-C) or high triglycerides (TG), is likely to play a major causative role in the residual risk of cardiovascular (cv) events in statin treated patient. As little recent information is available on the prevalence of persistent dyslipidemia in statin treated outpatients, this cross sectional survey will diminish this gap. METHODS: As part of a paneuropean study, 1255 patients in Germany pretreated with a statin for at least 3 months (45.4% with diabetes, 14.2% smoker) were included in the period of April and May 2008. Their cv risk profile was documented and modifiable risk factors were compared with current guidelines. RESULTS: A total of 39.9 % of patients had LDL-C levels below 100 mg/ml (median 106.7 mg/dl), 71.4% had HDL-C levels above 40 (males)/ 50(females) mg/dl (median 51 mg/dl), 66.5% with TG below 150 mg/dl (median 140,0 mg/dl). A total of 19.1% of patients had all 3 lipid values within the mentioned ranges. A total of 39.8% had blood pressure (RR) above 140/90 mmHg, 12.8% of patients had RR values below 140/90 mmHg and lipid levels within the desired ranges. BMI was 28.1 kg/m². CONCLUSIONS: Since 2000, comprehensive lipid management and treatment of modifiable risk factors in Germany has improved over time but remains still suboptimal and deserves further attention, which is similar to a prior report from German hospitals.